Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | SOD1 | P00441 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995983 | 0.92 | LMNA (0.62) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL2986350 | 0.86 | LMNA (0.65) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL20561234 | 0.86 | NR1H2 (0.76) | LMNACYP3A4NR1H2NR1H3SOD1 | |
| SCHEMBL2993726 | 0.86 | NR1H2 (0.76) | LMNACYP3A4NR1H2NR1H3SOD1 | |
| SCHEMBL2994378 | 0.86 | LMNA (0.65) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL24591878 | 0.86 | LMNA (0.65) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL2985191 | 0.85 | LMNA (0.64) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL2981668 | 0.85 | LMNA (0.64) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL2988945 | 0.84 | LMNA (0.62) | LMNACYP3A4NR1H2NR1H3PDE4D | |
| SCHEMBL2985198 | 0.84 | LMNA (0.67) | LMNACYP3A4NR1H2NR1H3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | US | claimed |
| US-7776558-B2 | Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776558-B2 | Human G protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125491-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders | GPR65, GPR3, GPR52 | LMNA 1175/4885CYP3A4 4826/4885NR1H2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.